Original articles

1

Osada T, Yamada A, Sasaki E, Utsugi T. Identification of dominant T-cell epitopes in the major Japanese cypress pollen allergen Cha o 3. Allergol Int. 2020 Jan;69(1):141-143. doi: 10.1016/j.alit.2019.07.008.

2

Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K, Uemura H, Nakagawa M, Nasu Y, Eto M, Suekane S, Sasada T, Shichijo S, Yamada A, Kakuma T, Itoh K. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunol Immunother, 2020 May;69(5):847-857. doi: 10.1007/s00262-020-02498-8.

3

Waki K, Kawano K, Tsuda N, Komatsu N, Yamada A. The CD4/CD8 ratio is a prognostic factor in IgG non-responders among peptide vaccine treated ovarian cancer patients. Cancer Sci, 2020 Apr;111(4):1124-1131. doi: 10.1111/cas.14349.

4

Suekane S, Yutani S, Yamada A, Sasada T, Matsueda S, Takamori S, Toh U, Kawano K, Yoshiyama K, Sakamoto S, Sugawara S, Komatsu N, Yamada T, Naito M, Terasaki M, Mine T, Itoh K, Shichijo S, Noguchi M. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients. Int J Oncol. 2020 Jun;56(6):1479-1489. doi: 10.3892/ijo.2020.5019.

5

Waki K, Yokomizo K, Kawano K, Tsuda N, Komatsu N, Yamada A. Integrity of plasma DNA is inversely correlated with vaccine-induced anti-tumor immunity in ovarian cancer patients. Cancer Immunol Immunother. 2020; 69(10), 2001-2007. doi: 10.1007/s00262-020-02599-4.

6

Toh U, Sakurai S, Saku S, Takao Y, Okabe M, Iwakuma N, Shichijo S, Yamada A, Itoh K, Akagi Y. Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancers. Cancer Sci. 2020 Aug;111(8):2760-2769. doi: 10.1111/cas.14510.

7

Waki K, Yokomizo K, Kawano K, Tsuda N, Komatsu N, Yamada A. Integrity of plasma cell-free DNA as a prognostic factor for vaccine therapy in patients with endometrial cancer. Mol Clin Oncol. 2021 Feb;14(2):29. doi: 10.3892/mco.2020.2191.

8

Waki K, Yokomizo K, Yoshiyama K, Takamori S, Komatsu N, Yamada A. Integrity of circulating cell-free DNA as a biomarker for vaccine therapy in patients with non-small cell lung cancer. Immunopharmacol Immunotoxicol. 43:2, 176-182, doi: 10.1080/08923973. 2021.1872619.

9

Uchino Y, Muroya D, Yoshitomi M, Shichijo S, Yamada A, Sasada T, Yamada T, Okuda K, Itoh K, Yutani S. Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer. Mol Clin Oncol. 2021 Feb;14(2):39. doi: 10.3892/mco.2020.2201.

10

Saku S, Toh U, Takao Y, Sakurai S, Yamada A, Shichijo S, Itoh K, Akagi Y. Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines. Exp Ther Med. 2021. 22(2): 905. doi: 10.3892/etm.2021.10337.

11

Sudo T, Kawahara A, Ishi K, Mizoguchi A, Nagasu S, Nakagawa M, Fujisaki M, Hino H, Saisho K, Kaku H, Matono S, Mori N, Akiba J, Yamada A, Akagi Y. Diversity and shared T-cell receptor repertoire analysis in esophageal squamous cell carcinoma. Oncol Lett. 2021. 22(2):618. doi: 10.3892/ol.2021.12879.